S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:TNXP

Tonix Pharmaceuticals (TNXP) Stock Price, News & Analysis

$0.19
-0.14 (-42.94%)
(As of 03/28/2024 ET)
Today's Range
$0.17
$0.34
50-Day Range
$0.19
$0.39
52-Week Range
$0.17
$4.00
Volume
21.83 million shs
Average Volume
1.78 million shs
Market Capitalization
$4.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.50

Tonix Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
2,857.0% Upside
$5.50 Price Target
Short Interest
Healthy
1.20% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.07mentions of Tonix Pharmaceuticals in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($8.58) to ($3.01) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.74 out of 5 stars

TNXP stock logo

About Tonix Pharmaceuticals Stock (NASDAQ:TNXP)

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company headquartered in Chatham, New Jersey. The company was founded in 2007 and then later went public in 2013. Tonix Pharmaceuticals is led by Seth Lederman who has been CEO since co-founding the company. Mr. Lederman was an Associate Professor at Columbia University for more than 2 decades before venturing into the private sector. Tonix Pharmaceuticals is his second venture, the first was bought out after developing an effective treatment for colorectal cancer. The company operates through three facilities located in Massachusetts, Maryland, and Montana.

The two east-coast facilities are the R&D center and the Advanced Development Center while manufacturing is located in Montana. The Maryland facility is rated BSL-2 with some areas rated BSL-3 which allows for the handling of live viruses. The Massachusetts facility is intended to enhance the company’s R&D and analytics capabilities as well as facilitate vaccine production at the clinical trial scale. The Montana facility will support Phase III trials as well as the mass production of approved treatments.

Tonix Pharmaceuticals focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering across a wide spectrum of ailments and treatments. Among them is COVID-19 for which the company has several products in development.

Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The types of diseases the company targets are widely occurring but hard to treat so breakthroughs of any kind could be significant sources of income. The company has several candidates in pre-clinical and clinical trials with two standouts that are on track for FDA approval. Resilient, a treatment for Fibromyalgia, and Prevail, a treatment for long-COVID, entered Phase III and Phase II trials in 2022.

The immunology portfolio includes treatments for organ transplant rejection, autoimmunity, and cancer, and several in this group have shown efficacy against multiple indications. The company’s infectious disease pipeline includes several promising treatments for viruses afflicting the world today. The TNX-80 vaccine is intended to prevent smallpox and monkeypox while TNX-1840 and TNX-1850 are live virus vaccines to fight COVID-19, as will TNX-3500 and TNX-102, which are small molecule antiviral drugs.

Tonix Pharmaceuticals CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction including Resilient, which is in mid-Phase 3 development for the management of fibromyalgia. Other products in the pipeline are TNX-1900 which is in development for the prevention of migraine headaches and TNX-1300 which is designed to treat cocaine intoxication.

TNXP Stock Price History

TNXP Stock News Headlines

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.
Tonix Pharmaceuticals Holding Corp
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.
3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond
See More Headlines
Receive TNXP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tonix Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/13/2023
Today
3/29/2024
Next Earnings (Estimated)
4/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:TNXP
Employees
117
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.50
High Stock Price Target
$8.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+2,857.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-110,220,000.00
Pretax Margin
-3,033.74%

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$22.51 per share

Miscellaneous

Free Float
26,639,000
Market Cap
$4.98 million
Optionable
Not Optionable
Beta
2.28
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Dr. Seth Lederman M.D. (Age 66)
    Co-Founder, President, CEO & Chairman
    Comp: $1.03M
  • Mr. Bradley Saenger CPA (Age 50)
    CFO & Treasurer
    Comp: $597.4k
  • Mrs. Jessica Edgar Morris
    Chief Operating Officer
  • Dr. Gregory M. Sullivan M.D. (Age 58)
    Chief Medical Officer & Secretary
    Comp: $591.12k
  • Dr. Herbert W. Harris M.D.
    Ph.D., Executive Vice President of Translational Medicine
  • Dr. Bruce L. Daugherty M.B.A. (Age 66)
    Ph.D., Executive Vice President of Research
    Comp: $300.38k
  • Ms. Siobhan Fogarty B.Sc.
    M.Sc., Executive Vice President of Product Development
  • Dr. Darryl Rideout Ph.D.
    Executive Vice President of Experimental Chemistry
  • Dr. Sina Bavari Ph.D.
    Executive Vice President of Infectious Disease Research & Development
  • Dr. Zeil Rosenberg M.D.
    M.P.H., Executive Vice President of Medical

TNXP Stock Analysis - Frequently Asked Questions

Should I buy or sell Tonix Pharmaceuticals stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tonix Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TNXP shares.
View TNXP analyst ratings
or view top-rated stocks.

What is Tonix Pharmaceuticals' stock price target for 2024?

2 Wall Street research analysts have issued twelve-month price objectives for Tonix Pharmaceuticals' stock. Their TNXP share price targets range from $3.00 to $8.00. On average, they anticipate the company's stock price to reach $5.50 in the next twelve months. This suggests a possible upside of 2,857.0% from the stock's current price.
View analysts price targets for TNXP
or view top-rated stocks among Wall Street analysts.

How have TNXP shares performed in 2024?

Tonix Pharmaceuticals' stock was trading at $0.4030 at the beginning of the year. Since then, TNXP stock has decreased by 53.8% and is now trading at $0.1860.
View the best growth stocks for 2024 here
.

Are investors shorting Tonix Pharmaceuticals?

Tonix Pharmaceuticals saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 967,000 shares, an increase of 56.9% from the February 29th total of 616,200 shares. Based on an average daily volume of 1,570,000 shares, the days-to-cover ratio is presently 0.6 days. Currently, 1.2% of the company's shares are sold short.
View Tonix Pharmaceuticals' Short Interest
.

When is Tonix Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, April 1st 2024.
View our TNXP earnings forecast
.

How were Tonix Pharmaceuticals' earnings last quarter?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) announced its quarterly earnings data on Monday, March, 13th. The company reported ($3.50) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($5.38) by $1.88.

When did Tonix Pharmaceuticals' stock split?

Tonix Pharmaceuticals shares reverse split on the morning of Wednesday, May 10th 2023. The 1-6.25 reverse split was announced on Wednesday, May 10th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, May 10th 2023. An investor that had 100 shares of stock prior to the reverse split would have 16 shares after the split.

What other stocks do shareholders of Tonix Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tonix Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Vaxart (VXRT), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Rite Aid (RAD), Heat Biologics (HTBX), Matinas BioPharma (MTNB), Bionano Genomics (BNGO), VBI Vaccines (VBIV) and ADMA Biologics (ADMA).

Who are Tonix Pharmaceuticals' major shareholders?

Tonix Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Armistice Capital LLC (14.09%). Insiders that own company stock include Daniel Wintner Goodman and Seth Lederman.
View institutional ownership trends
.

How do I buy shares of Tonix Pharmaceuticals?

Shares of TNXP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TNXP) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners